Browse > Article

Which Dosing Scheme is Suitable for the Taxanes\ulcorner An in Vitro Model  

Sanli, Ulus-Ali (Ege University Medical School, Department of Medical Oncology)
Uslu, Ruchan (Ege University Medical School, Department of Medical Oncology)
Karabulut, Bulent (Ege University Medical School, Department of Medical Oncology)
Sezgin, Canfeza (Ege University Medical School, Department of Medical Oncology)
Saydam, Guray (Ege University Medical School, Department of Hematology)
Omay, Serdar-Bedii (Ege University Medical School, Department of Hematology)
Goker, Erdem (Ege University Medical School, Department of Medical Oncology)
Publication Information
Archives of Pharmacal Research / v.25, no.4, 2002 , pp. 550-555 More about this Journal
Abstract
The discovery and development of the taxane class of antitumor compounds represent significant advances in the treatment of patients with a variety of malignancies. These drugs are effectively used in the treatment of breast cancer. In this study we evaluated the efficacy of fractionated usage of both paclitaxel and docetaxel as a single agent in the breast cancer cell line MCF-7. It has been shown that the cytotoxic effect of paclitaxel was increased when the divided $IC_{50}$ concentrations were used sequentially and in contrast to paclitaxel, cytotoxic effect of docetaxel was decreased with the same schema and the single dose of $IC_{50}$ concentration was optimal. The cause of the difference between the cytotoxic effects of two agents with this schedule is obscure. Demonstrating mechanisms, which are responsible for these differences, will be important for more rational use of taxoids and to provide basis for the following clinical trials.
Keywords
Breast cancer; Docetaxel; Mcf-7; Paclitaxel; Cytotoxicity;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Warburton, S., and James, R., Haemocytometer cell counts and viability studies. In: Doyle, A., Grifits, J. B., and Newell D. G. (eds.), Cell and tissue culture laboratory procedures, Chichester, John Wiley, pp. 411-415 (1994)
2 Nabholtz, J. M., Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin. Oncol., 26, 7-13 (1999)   PUBMED
3 Carlson, R. W., Quality of life issues in the treatment of metastatic breast cancer. Oncology, 12, 27-31 (1998)
4 Carmichael, J., Jones, A., and Hutchinson, T., A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. Semin. Oncol., 24, 44-47 (1997)
5 Cortes, J. E., Pazdur, and R., Docetaxel. J. Clin. Oncol., 13, 2643- 2655 (1995)   DOI   PUBMED
6 Greenberg, P. A., Hortobagyi, G. N., Smith, T. L., Ziegler, L. D., Frye, D. K., and Buzdar, A. U., Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin. Oncol., 14, 2197-2205 (1996)   DOI   PUBMED
7 Mullins, D. W., Walker, T. M., Burger, C. J. and Elgert, K. D., Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities. Cancer. Immunol. Immunother., 45, 20-28 (1997)   DOI   ScienceOn
8 Rowinsky, E. K., The taxanes: dosing and scheduling considerations. Oncology, 11, 7-19 (1997)
9 Hainsworth, J. D., Burris, H. A., Erland, J. B., Thomas, M., and Greco, F. A., Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol., 16, 2164-2168 (1998)   DOI   PUBMED
10 Valero, V., Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin. Oncol., 24, 13-18 (1997)
11 Von Hoff, D. D.,The taxoids: same roots, different drugs. Semin. Oncol., 24, 3-13(1997)   PUBMED
12 White, C. M., Martin, B. K., Lee, L. F., Haskill, J. S., and Ting, J.P., Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer. Immunol. Immunother., 46, 104-112 (1998)   DOI   ScienceOn
13 Hainsworth, J. D., Burris, H. A., and Greco, F. A., Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin. Oncol., 26, 19-24 (1999)   PUBMED
14 Seidman, A. D., Hudis, C. A., Albanel, J., Tong, W., Tepler, I., Currie, V., Moynahan, M. E., Theodoulou, M., Gollub, M., Baselga, J., and Norton, L., Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16, 3353-3361 (1998)   DOI   PUBMED
15 Nabholtz, J. M., Tonkin, K., Smylie, M., Au, H. J., Lindsay, M. A., and Mackey, J., Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer? Exp. Opin. Pharmacother., 1, 187-206 (2000)   DOI   ScienceOn
16 Burkhart, C. A., Berman, J. W., Swindell, C. S., and Horwitz, S. B., Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-a gene expression and cytotoxicity. Cancer Res., 54, 5779-5782 (1994)   PUBMED
17 Hansen, M. B., Nielsen, S. E., and Berg, K., Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods, 119, 203-210 (1989)   DOI   ScienceOn
18 Jassem, J., Pienkowski, T., Pluzanska, A., Jelic, S., Gorbunova, V., Mrsic, Z., -K., Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., Munier, S., and Weil, C., Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J. Clin. Oncol., 19, 1707-1715 (2001)   DOI   PUBMED
19 Perez, E.A., Current management of metastatic breast cancer. Semin. Oncol, 26, 1-10 (1999)   PUBMED
20 Stemmler, H. J., Gutschow, K., Sommer, H., Malekmohammadi, M., Kentenich, C. H., Forstpointner, R, Geuenich, S., Bischoff, J., Hiddemann, W., and Heinemann, V., Weekly docetaxel (Taxotereo) in patients with metastatic breast cancer. Ann. Oncol., 12, 1393-1398 (2001)   DOI   ScienceOn
21 Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J. G., Gamucci, T., Houston, S., Coleman, R., Schachter, J., Vreckem, A., Sylvester, R., Awada, A., Wildiers, J., and Piccart, M., Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol., 18, 724-733 (2000)   DOI   PUBMED
22 Klaassen, U., Wilke, H., Strumberg, D., Eberhardt, W., Korn, M., and Seeber, S., Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur. J. Cancer, 32, 547-549(1996)   DOI   ScienceOn
23 Pazdur, R., Kudelka, A.P., Kavanagh, J.J., Cohen, P.R., and Raber, M.N., The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer. Treat. Rev., 19, 351-386 (1993)   DOI   ScienceOn
24 Lembersky, B. C., Anderson, S., Smith, R., Brown, A., Nesbitt, L., Aikin, J., Fehrenbacher, L., Jochimsen, P., Thirlwell, M. P., and Mamounas, E.P., Phase II trial of doxorubicin and docetaxel for locally advanced and metastatic breast cancer: preliminary results from NSABP BP-57. Proc. Am. Soc. Clin. Oncol., 19, 403 (2000)
25 Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., and Winer, E. P. Docetaxel administered on a weekly basis for metastatic breast cancer. J. Clin. Oncol., 18, 1212-1219 (2000)   DOI   PUBMED
26 Esteva, F. J., Valero, V., Pusztai, L., Boehnke, L.,-M., Buzdar, A. U., and Hortobagyi,G. N., Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. The Oncologist, 6, 133-146 (2001)   DOI   ScienceOn
27 Chang, A. Y., Boros, L., Asbury, R., Hui, L., and Rubins, J., Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin. Oncol., 24, 17-71 (1997)   PUBMED